OR WAIT 15 SECS
Cambrex invests in development and laboratory facilities and adds staff.
Cambrex announced plans to expand chemical and analytical development capabilities at its Charles City, Iowa plant, part of the API manufacturer’s strategy to increase its development capacity and resources in North America. The facility manufactures APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.
The company will construct an additional 2000-sq-ft. of laboratory space for development projects and will hire 14 chemists. The building, installation, and validation of equipment is expected to be completed by the first quarter of 2018, the company reported in a Jan. 30, 2018 press release.
In 2017, the company announced expansions at its High Point, NC facility including a 11,000-sq.-ft. analytical laboratory and 400-sq.-ft. pilot plant with a reactor capacity of 4000 L. The High Point site produces complex APIs and intermediates in batch sizes from milligrams to 100kg to support clinical trials.
“The Charles City site has seen multiple investments and expansions in manufacturing capacity over the past five years to meet market demand, and this in turn, has led to us needing to increase the capacity of the supporting development and analytical functions,” commented Joe Nettleton, vice-president US operations, Cambrex, in the press release. “Our strategy in expanding the development capabilities across the sites at both Charles City and High Point is to ensure both facilities are harmonized and can function synergistically so that projects can be seamlessly transferred between the two.”
Source: Cambrex Corporation